84 related articles for article (PubMed ID: 33024084)
21. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
[TBL] [Abstract][Full Text] [Related]
22. Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL).
Borlenghi E; Pagani C; Zappasodi P; Bernardi M; Basilico C; Cairoli R; Fracchiolla N; Todisco E; Turrini M; Cattaneo C; Da Vià M; Ciceri F; Passamonti F; Mancini V; Sciumè M; Cerqui E; Sciumè M; Rossi G
J Geriatr Oncol; 2021 May; 12(4):550-556. PubMed ID: 33097455
[TBL] [Abstract][Full Text] [Related]
23. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
Bazinet A; Assouline S
Expert Rev Hematol; 2021 Feb; 14(2):185-197. PubMed ID: 33430671
[No Abstract] [Full Text] [Related]
24. Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma.
Szafer-Glusman E; Liu J; Sinha A; Peale FV; Ray J; Horn C; Oestergaard MZ; Kornacker M; Sehn LH; Vitolo U; Knapp A; Venstrom J; Byrtek M; Punnoose E
Leuk Lymphoma; 2021 Apr; 62(4):999-1002. PubMed ID: 33325309
[No Abstract] [Full Text] [Related]
25. Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers.
Veeraraghavan H; Friedman CF; DeLair DF; Ninčević J; Himoto Y; Bruni SG; Cappello G; Petkovska I; Nougaret S; Nikolovski I; Zehir A; Abu-Rustum NR; Aghajanian C; Zamarin D; Cadoo KA; Diaz LA; Leitao MM; Makker V; Soslow RA; Mueller JJ; Weigelt B; Lakhman Y
Sci Rep; 2020 Oct; 10(1):17769. PubMed ID: 33082371
[TBL] [Abstract][Full Text] [Related]
26. Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups.
Bogani G; Apolone G; Ditto A; Scambia G; Panici PB; Angioli R; Pignata S; Greggi S; Scollo P; Delia M; Franchi M; Martinelli F; Signorelli M; Lopez S; Di Donato V; Valabrega G; Ferrandina G; Palaia I; Bergamini A; Bocciolone L; Savarese A; Ghezzi F; Casarin J; Pinelli C; Trojano V; Chiantera V; Giorda G; Sopracordevole F; Malzoni M; Salerno G; Sartori E; Testa A; Zannoni G; Zullo F; Vizza E; Trojano G; Chiantera A; Raspagliesi F
J Gynecol Oncol; 2020 Nov; 31(6):e92. PubMed ID: 33078597
[TBL] [Abstract][Full Text] [Related]
27. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Rautenberg C; Stölzel F; Röllig C; Stelljes M; Gaidzik V; Lauseker M; Kriege O; Verbeek M; Unglaub JM; Thol F; Krause SW; Hänel M; Neuerburg C; Vucinic V; Jehn CF; Severmann J; Wass M; Fransecky L; Chemnitz J; Holtick U; Schäfer-Eckart K; Schröder J; Kraus S; Krüger W; Kaiser U; Scholl S; Koch K; Henning L; Kobbe G; Haas R; Alakel N; Röhnert MA; Sockel K; Hanoun M; Platzbecker U; Holderried TAW; Morgner A; Heuser M; Sauer T; Götze KS; Wagner-Drouet E; Döhner K; Döhner H; Schliemann C; Schetelig J; Bornhäuser M; Germing U; Schroeder T; Middeke JM
Blood Cancer J; 2021 Oct; 11(10):164. PubMed ID: 34608129
[TBL] [Abstract][Full Text] [Related]
28. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
Benitez LL; Perissinotti AJ; Rausch CR; Klaus J; Clark SM; Filtz M; Ratermann K; Treptow C; Griffin S; Olson M; Crain M; Kadia T; Pettit K; Burke PW; Bixby DL; Marini BL
Leuk Lymphoma; 2021 Sep; 62(9):2184-2192. PubMed ID: 33830856
[TBL] [Abstract][Full Text] [Related]
29. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
[TBL] [Abstract][Full Text] [Related]
30. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Polverelli N; Elli EM; Abruzzese E; Palumbo GA; Benevolo G; Tiribelli M; Bonifacio M; Tieghi A; Caocci G; D'Adda M; Bergamaschi M; Binotto G; Heidel FH; Cavazzini F; Crugnola M; Pugliese N; Bosi C; Isidori A; Bartoletti D; Auteri G; Latagliata R; Gandolfi L; Martino B; Scaffidi L; Cattaneo D; D'Amore F; Trawinska MM; Stella R; Markovic U; Catani L; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Vianelli N; Breccia M; Russo D; Cavo M; Iurlo A; Palandri F
Br J Haematol; 2021 Apr; 193(2):356-368. PubMed ID: 33222197
[TBL] [Abstract][Full Text] [Related]
31. Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia.
Loke J; Vyas H; Craddock C
Front Oncol; 2021; 11():666091. PubMed ID: 33937080
[TBL] [Abstract][Full Text] [Related]
32. Emerging agents and regimens for AML.
Liu H
J Hematol Oncol; 2021 Mar; 14(1):49. PubMed ID: 33757574
[TBL] [Abstract][Full Text] [Related]
33. New Treatment Options for Older Patients with Acute Myeloid Leukemia.
Saxena K; Konopleva M
Curr Treat Options Oncol; 2021 Mar; 22(5):39. PubMed ID: 33743079
[TBL] [Abstract][Full Text] [Related]
34. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Craddock C; Jackson A; Loke J; Siddique S; Hodgkinson A; Mason J; Andrew G; Nagra S; Malladi R; Peniket A; Gilleece M; Salim R; Tholouli E; Potter V; Crawley C; Wheatley K; Protheroe R; Vyas P; Hunter A; Parker A; Wilson K; Pavlu J; Byrne J; Dillon R; Khan N; McCarthy N; Freeman SD
J Clin Oncol; 2021 Mar; 39(7):768-778. PubMed ID: 33373276
[TBL] [Abstract][Full Text] [Related]
35. Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
Lemoli RM; Montesinos P; Jain A
Crit Rev Oncol Hematol; 2023 May; 185():103984. PubMed ID: 37028531
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
[TBL] [Abstract][Full Text] [Related]
37. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
[TBL] [Abstract][Full Text] [Related]
38. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Bhatt DL; Szarek M; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Verma S; Lapuerta P; Pitt B;
N Engl J Med; 2021 Jan; 384(2):117-128. PubMed ID: 33200892
[TBL] [Abstract][Full Text] [Related]
39. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL; Szarek M; Pitt B; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Inzucchi SE; Kosiborod MN; Cherney DZI; Dwyer JP; Scirica BM; Bailey CJ; Díaz R; Ray KK; Udell JA; Lopes RD; Lapuerta P; Steg PG;
N Engl J Med; 2021 Jan; 384(2):129-139. PubMed ID: 33200891
[TBL] [Abstract][Full Text] [Related]
40. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
Docherty KF; Jhund PS; Bengtsson O; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
Diabetes Care; 2020 Nov; 43(11):2878-2881. PubMed ID: 33082245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
